Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings results on February 12, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $5.03, beating the consensus estimate of $4.85 by $0.18 per share. Revenue came in at $3.2B, beating the estimate of $3.2B.
Vertex Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $491.47 with a market capitalization of $114.5B.